Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Seagen Inc's Business Segments
Seagen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 649
Regions Reported
-
Seagen Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product88%
- Royalty9.8%
- License and Service2.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 571 | 88% |
| Royalty | $ 64 | 9.8% |
| License and Service | $ 14 | 2.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Seagen Inc
Seagen Inc., formerly known as Seattle Genetics, is an American biotechnology company founded in 1998 and headquartered in Bothell, Washington.
The company's primary focus is on developing and commercializing innovative, targeted therapies for the treatment of cancer and other challenging diseases.
Seagen's primary product is ADCETRIS (brentuximab vedotin), which is an antibody-drug conjugate (ADC) that delivers the chemotherapy drug directly to cancer cells.
ADCETRIS has been approved for the treatment of several different types of cancer, including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma.
Seagen has also developed several other ADCs that are in various stages of clinical development.
These include tucatinib, which is in Phase 3 clinical trials for the treatment of HER2-positive breast cancer; ladiratuzumab vedotin, which is in Phase 2 trials for the treatment of triple-negative breast cancer; and datopotamab deruxtecan, which is in Phase 1 trials for the treatment of various solid tumors.
Aside from ADCs, Seagen has also developed proprietary technologies for antibody-drug conjugate production, including its proprietary linker and cytotoxic payload technologies that enable a higher therapeutic index and greater specificity for tumor cells.
Seagen has partnerships with various pharmaceutical companies, including Takeda Pharmaceutical Company, Astellas Pharma, and Merck.
The company has also received funding from the National Cancer Institute and various venture capital firms.
In conclusion, Seagen Inc.
is a biotechnology company that specializes in the development and commercialization of targeted therapies for cancer and other diseases, with a primary focus on antibody-drug conjugates.
The company's flagship product is ADCETRIS, and it has several other products in various stages of clinical development.
Its proprietary technologies for ADC production give it a unique advantage in the field, and it has partnerships and funding from various large pharmaceutical companies and organizations.
The company's primary focus is on developing and commercializing innovative, targeted therapies for the treatment of cancer and other challenging diseases.
Seagen's primary product is ADCETRIS (brentuximab vedotin), which is an antibody-drug conjugate (ADC) that delivers the chemotherapy drug directly to cancer cells.
ADCETRIS has been approved for the treatment of several different types of cancer, including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma.
Seagen has also developed several other ADCs that are in various stages of clinical development.
These include tucatinib, which is in Phase 3 clinical trials for the treatment of HER2-positive breast cancer; ladiratuzumab vedotin, which is in Phase 2 trials for the treatment of triple-negative breast cancer; and datopotamab deruxtecan, which is in Phase 1 trials for the treatment of various solid tumors.
Aside from ADCs, Seagen has also developed proprietary technologies for antibody-drug conjugate production, including its proprietary linker and cytotoxic payload technologies that enable a higher therapeutic index and greater specificity for tumor cells.
Seagen has partnerships with various pharmaceutical companies, including Takeda Pharmaceutical Company, Astellas Pharma, and Merck.
The company has also received funding from the National Cancer Institute and various venture capital firms.
In conclusion, Seagen Inc.
is a biotechnology company that specializes in the development and commercialization of targeted therapies for cancer and other diseases, with a primary focus on antibody-drug conjugates.
The company's flagship product is ADCETRIS, and it has several other products in various stages of clinical development.
Its proprietary technologies for ADC production give it a unique advantage in the field, and it has partnerships and funding from various large pharmaceutical companies and organizations.
Seagen Inc. is a leading global biotechnology company that concentrates on the development and commercialization of innovative therapies for cancer treatment. The companys offerings span across three main segments: Oncology, Immunology, and Hematology, each focusing on distinct therapeutic areas and leveraging advanced biotechnological approaches.
1. Oncology
The Oncology segment is at the heart of Seagen’s mission to deliver targeted therapies that specifically address a range of cancer types. Key products within this segment include:
- Adcetrise (brentuximab vedotin): Adcetrise is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting CD30 with a potent cytotoxic agent. It is approved for the treatment of Hodgkin lymphoma and certain types of anaplastic large cell lymphoma. The mechanism of action involves delivering the chemotherapy agent directly to the cancer cells, which enhances efficacy while minimizing systemic toxicity.
- Tukysa (tucatinib): Designed for the treatment of HER2-positive breast cancer, Tukysa is an oral tyrosine kinase inhibitor that selectively targets the HER2 receptor. This targeted approach helps inhibit cancer cell proliferation and survival. It is often used in combination with other therapies to enhance treatment outcomes.
- Padcev (enfortumab vedotin-ejfv): Another ADC, Padcev targets Nectin-4, a protein commonly expressed in urothelial carcinoma. By delivering a potent cytotoxic agent to cancer cells expressing Nectin-4, Padcev provides an effective treatment option for patients with advanced urothelial cancer, demonstrating substantial therapeutic benefits.
Immunology
Seagen’s Immunology segment focuses on harnessing the bodys immune system to combat cancer. This area includes several innovative therapies such as:
- Seviprotimut-L (formerly known as SGN-2FF): Currently in clinical trials, Seviprotimut-L is aimed at enhancing the immune response against cancer. It is designed as an immunotherapeutic agent to stimulate the immune system and is under investigation for its application in treating bladder cancer, among other malignancies.
- TLR7 Agonists: These compounds are small molecules designed to activate Toll-like receptor 7 (TLR7), which plays a crucial role in the immune system’s response to cancer. By promoting immune stimulation, TLR7 agonists aim to enhance the bodys ability to recognize and destroy cancer cells.
Hematology
The Hematology segment of Seagen focuses on therapies aimed at treating blood cancers and disorders. The notable products in this segment include:
- Adcetrise (brentuximab vedotin): As previously mentioned, this therapy is particularly significant for its efficacy against lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma, underscoring its versatility within Seagen’s portfolio.
- Turalio (pexidartinib): This innovative therapy is indicated for tenosynovial giant cell tumor, a rare and locally aggressive tumor affecting the synovial lining of joints and tendons. Turalio operates as a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R), thereby impacting the tumor microenvironment and contributing to disease control.
Additional Services
Beyond its product offerings, Seagen provides a variety of support services integral to the development and commercialization of its therapies. These services encompass:
- Clinical Trial Design: Seagen collaborates with various stakeholders to design and implement robust clinical trials that support the regulatory approval and clinical use of its products.
- Regulatory Affairs: The company maintains a dedicated regulatory affairs team that ensures compliance with global regulatory standards while facilitating the submission of necessary documentation for new therapies.
- Medical Affairs: Seagen’s medical affairs team works to disseminate clinical data and scientific information to healthcare professionals, bolstering the understanding and proper use of its therapies.
Research and Development Focus
Seagen Inc. prides itself on a strong research and development (R&D) pipeline, with multiple candidates at various stages of development. These efforts are geared toward advancing innovative treatments that drastically improve outcomes for patients with cancer, emphasizing the companys commitment to scientific excellence and patient care.
Overall, Seagen Inc. is strategically positioned within the biotechnology landscape, leveraging its expertise in targeted therapies, immunology, and hematology to make significant contributions to cancer treatment and patient management.
1. Oncology
The Oncology segment is at the heart of Seagen’s mission to deliver targeted therapies that specifically address a range of cancer types. Key products within this segment include:
- Adcetrise (brentuximab vedotin): Adcetrise is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting CD30 with a potent cytotoxic agent. It is approved for the treatment of Hodgkin lymphoma and certain types of anaplastic large cell lymphoma. The mechanism of action involves delivering the chemotherapy agent directly to the cancer cells, which enhances efficacy while minimizing systemic toxicity.
- Tukysa (tucatinib): Designed for the treatment of HER2-positive breast cancer, Tukysa is an oral tyrosine kinase inhibitor that selectively targets the HER2 receptor. This targeted approach helps inhibit cancer cell proliferation and survival. It is often used in combination with other therapies to enhance treatment outcomes.
- Padcev (enfortumab vedotin-ejfv): Another ADC, Padcev targets Nectin-4, a protein commonly expressed in urothelial carcinoma. By delivering a potent cytotoxic agent to cancer cells expressing Nectin-4, Padcev provides an effective treatment option for patients with advanced urothelial cancer, demonstrating substantial therapeutic benefits.
Immunology
Seagen’s Immunology segment focuses on harnessing the bodys immune system to combat cancer. This area includes several innovative therapies such as:
- Seviprotimut-L (formerly known as SGN-2FF): Currently in clinical trials, Seviprotimut-L is aimed at enhancing the immune response against cancer. It is designed as an immunotherapeutic agent to stimulate the immune system and is under investigation for its application in treating bladder cancer, among other malignancies.
- TLR7 Agonists: These compounds are small molecules designed to activate Toll-like receptor 7 (TLR7), which plays a crucial role in the immune system’s response to cancer. By promoting immune stimulation, TLR7 agonists aim to enhance the bodys ability to recognize and destroy cancer cells.
Hematology
The Hematology segment of Seagen focuses on therapies aimed at treating blood cancers and disorders. The notable products in this segment include:
- Adcetrise (brentuximab vedotin): As previously mentioned, this therapy is particularly significant for its efficacy against lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma, underscoring its versatility within Seagen’s portfolio.
- Turalio (pexidartinib): This innovative therapy is indicated for tenosynovial giant cell tumor, a rare and locally aggressive tumor affecting the synovial lining of joints and tendons. Turalio operates as a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R), thereby impacting the tumor microenvironment and contributing to disease control.
Additional Services
Beyond its product offerings, Seagen provides a variety of support services integral to the development and commercialization of its therapies. These services encompass:
- Clinical Trial Design: Seagen collaborates with various stakeholders to design and implement robust clinical trials that support the regulatory approval and clinical use of its products.
- Regulatory Affairs: The company maintains a dedicated regulatory affairs team that ensures compliance with global regulatory standards while facilitating the submission of necessary documentation for new therapies.
- Medical Affairs: Seagen’s medical affairs team works to disseminate clinical data and scientific information to healthcare professionals, bolstering the understanding and proper use of its therapies.
Research and Development Focus
Seagen Inc. prides itself on a strong research and development (R&D) pipeline, with multiple candidates at various stages of development. These efforts are geared toward advancing innovative treatments that drastically improve outcomes for patients with cancer, emphasizing the companys commitment to scientific excellence and patient care.
Overall, Seagen Inc. is strategically positioned within the biotechnology landscape, leveraging its expertise in targeted therapies, immunology, and hematology to make significant contributions to cancer treatment and patient management.